Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

The clinical utility of inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is required for the production of androgens, has been exemplified by the approval of abiraterone for the treatment of castration-resistant prostate cancer (CRPC). Recently, however, it has been reported th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Norris, John D., Ellison, Stephanie J., Baker, Jennifer G., Stagg, David B., Wardell, Suzanne E., Park, Sunghee, Alley, Holly M., Baldi, Robert M., Yllanes, Alexander, Andreano, Kaitlyn J., Stice, James P., Lawrence, Scott A., Eisner, Joel R., Price, Douglas K., Moore, William R., Figg, William D., McDonnell, Donald P.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5451248/
https://ncbi.nlm.nih.gov/pubmed/28463227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87328
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars